SummaryThe normal pancreas harbors heterogeneous fibroblast populations. Lineage tracing of these populations has shown differential contribution to the fibrotic response that accompanies pancreatic carcinogenesis. We show that Gli1 fibroblasts, which are present but rare in the normal pancreas, expand during pancreatic carcinogenesis.

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that is projected to become the second leading cause of cancer-related death by 2030.[@bib1] The 5-year survival rate for PDAC is only 10%, which can be attributed to the aggressive and chemoresistant nature of the cancer, in addition to the frequently late diagnosis.[@bib2] In PDAC, more so than in other solid tumors, a high percentage of the tumor volume is occupied by nonmalignant cells that form the tumor stroma.[@bib3] The cellular component of the stroma includes fibroblasts, infiltrating immune cells, vascular elements, and nerves.[@bib4] This fibroinflammatory environment develops during the early steps of tumorigenesis and supports tumor growth and metastasis, although the roles of the individual components are still not fully understood.[@bib4]

Fibroblasts are a prominent and active cellular component of the stroma; they contribute to the secretion of extracellular matrix, and produce chemokines and growth factors that affect immune, endothelial, and cancer cell growth and function.[@bib4], [@bib5], [@bib6] Initially, research into pancreatic cancer-associated fibroblasts (CAFs) supported a unilateral protumorigenic role.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12] However, other results suggested that fibroblasts could restrain tumor formation and that depleting them might accelerate carcinogenesis.[@bib13] This paradox might be explained by the observation that fibroblasts are not a homogenous population, but exist in subsets with different roles.[@bib14], [@bib15], [@bib16], [@bib17]

Analysis into fibroblast heterogeneity has made considerable progress with the advent of single-cell sequencing (for review see Helms et al[@bib18] and Sahai et al.[@bib19] Lately, a number of research groups have identified fibroblast subpopulations, characterized by distinct patterns of gene expression, in both human and mouse PDAC tissue.[@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25] Even in the developing pancreas, distinct fibroblast populations were observed.[@bib26] However, which type(s) of fibroblasts in the healthy pancreas gives rise to CAFs remains an open question. Although pancreatic CAFs have long been assumed to derive from the resident pancreatic stellate cells, no formal lineage tracing has been conducted to support this idea. The healthy pancreas also contains fibroblasts in periacinar, perivascular, and periductal regions. The potential of these resident cells in populating the fibroinflammatory environment and shaping the heterogeneity of the pancreatic cancer-associated stroma is unknown, in part because of the scarcity of markers identifying specific fibroblast populations.

Here, we describe 2 fibroblast populations that are present in the healthy pancreas, marked by the expression of Gli1 and Hoxb6. Gli1 is a zinc-finger transcription factor and downstream effector and target gene of the Hedgehog signaling pathway, which is up-regulated in human and mouse pancreatic cancer.[@bib27], [@bib28], [@bib29] We previously described a small population of Gli1^+^ fibroblasts in the healthy pancreas.[@bib27]^,^[@bib30] In a number of other organs, tissue-resident Gli1^+^ cells are mesenchymal progenitors that associate closely with the vasculature until activation into proliferative myofibroblasts by injury.[@bib31], [@bib32], [@bib33], [@bib34], [@bib35] We sought to determine whether Gli1^+^ fibroblasts similarly proliferate in the pancreas in response to neoplasia. In contrast, Hoxb6 marks the entirety of the mesenchyme during pancreas development,[@bib36] but its expression is restricted to a subset of fibroblasts in the adult pancreas. Importantly, Gli1 and Hoxb6 are expressed in largely separate populations in the healthy pancreas. We used lineage tracing and dual recombinase approaches to follow the fate of each cell population during carcinogenesis and determined that Gli1^+^ cells proliferated and contributed to the fibrotic reaction in pancreatic cancer, whereas Hoxb6^+^ cells did not.

Results {#sec1}
=======

Gli1^+^ Fibroblasts Are Present in the Healthy and Neoplastic Pancreas {#sec1.1}
----------------------------------------------------------------------

Pancreatic stellate cells (PSCs) have long been presumed to be the predominant mesenchymal population in the healthy pancreas.[@bib37] Because Gli1^+^ cells have not been described as stellate cells,[@bib32] we sought to confirm the existence of different types of resident fibroblasts within the pancreas. PSCs, similar to hepatic stellate cells, store vitamin A in lipid droplets in the cytoplasm,[@bib38] and these are visible as electron-dense inclusions in transmission electron microscopy (TEM) images. We used TEM to visualize the mesenchymal populations of the healthy mouse pancreas and observed not only PSCs (with lipid droplets) but also fibroblasts (devoid of lipid droplets) ([Figure 1](#fig1){ref-type="fig"}*A*).Figure 1**Gli1**^**+**^**fibroblasts are present in the healthy and neoplastic pancreas.** (*A*) TEM images of a healthy mouse pancreas. *Black squares* and *arrows* indicate sections that are magnified. (*B*) Genetic scheme for the knock-in Gli1^EGFP/+^ reporter mouse. (*C*) Immunohistochemical staining for GFP and IF staining of GFP (green), αSMA (red), and amylase (pink); and GFP (green), PDGFRβ (red), and CK19 (pink) in healthy Gli1^EGFP/+^ mice and wild-type (*inset*) mice. *Scale bar*: 50 um. (*D*) Genetic scheme for the Ptf1a^FlpO/+^;Kras^FRT-stop-FRT-G12D/+^;Gli1^EGFP/+^ (KF;Gli1^EGFP/+^) mouse. (*E*) IHC staining for GFP and the IF staining panels in KF;Gli1^EGFP/+^ and KF-negative control (*inset*) mice after 3 weeks of cerulein-induced acute pancreatitis. (*F*) Genetic scheme for the KF;Trp53^FRT-stop-FRT/+^,Gli1^EGFP/+^ (KPF;Gli1^EGFP/+^) mouse. (*G*) IHC staining for GFP and the IF staining panels in KPF;Gli1^EGFP/+^ and KPF-negative control (*inset*) mice after evidence of disease burden. (*H*) Representative flow cytometry plot of GFP against PDGFR⍺, gated on 4′,6-diamidino-2-phenylindole (DAPI)^-^ CD45^-^ cells, and quantification of the percentage of GFP^+^ PDGFR⍺^+^ cells at the different disease stages (n ≥ 5). All data are expressed as means ± SEM. a, acinar cell; AMY, amylase; CK19, cytokeratin 19; d, duct; EGFP, enhanced green fluorescent protein; fb, fibroblast; PSC, pancreatic stellate cell; v, blood vessel.

By using a Gli1^enhanced\ green\ fluorescent\ protein\ (EGFP)/+^ reporter, we conducted a detailed analysis of Gli1 expression in the normal pancreas, in precursor lesions called *pancreatic intraepithelial neoplasia* (PanIN), and in pancreatic cancer. First, we examined the pancreata of healthy young adult mice between 4 and 8 weeks of age that were heterozygous for Gli1^EGFP/+^. Gli1^EGFP/+^ is a knock-in allele that faithfully recapitulates the expression of the endogenous locus ([Figure 1](#fig1){ref-type="fig"}*B*). The mice lack 1 functional allele of Gli1 but nevertheless are viable and fertile.[@bib39] Because the natural fluorescence of EGFP does not persist after fixation and paraffin embedding, we used an anti--green fluorescent protein antibody to visualize the reporter expression in immunohistochemistry (IHC) or immunofluorescence (IF). We observed Gli1^+^ cells in a perivascular location in the healthy pancreas, in a similar position previously described in the kidney, liver, lung, heart, and bone[@bib31]^,^[@bib32]^,^[@bib35] ([Figure 1](#fig1){ref-type="fig"}*C*). IF staining with α-smooth muscle actin (⍺SMA) and platelet-derived growth factor receptor β (PDGFRβ), both fibroblast markers, indicated that, as previously described for the Hedgehog target gene Ptch1,[@bib40] Gli1 is expressed in pancreatic fibroblasts ([Figure 1](#fig1){ref-type="fig"}*C*). Conversely, we observed no expression of the EGFP reporter in amylase-expressing acinar cells.

A well-established model for pancreatic carcinogenesis involves the targeted expression of mutant *Kras* in the murine pancreas. Oncogenic mutations in *Kras* are a near-universal feature of human pancreatic cancer and occur early during disease progression.[@bib41]^,^[@bib42] Expression of mutant *Kras* in genetically engineered mice leads to the formation of PanIN lesions that can progress to invasive disease over time. To evaluate Gli1 in PanIN lesions, we crossed Ptf1a^codon\ optimized\ Flp\ recombinase\ (FlpO)/+^;Kirsten rat sarcoma viral oncogene analog (Kras)^FRT-stop-FRT\ (FSF)-G12D/+^ (KF) mice with the Gli1^EGFP/+^ reporter, generating KF;Gli1^EGFP/+^ mice ([Figure 1](#fig1){ref-type="fig"}*D*). KF mice,[@bib43] similar to their counterpart Pdx1^Cre^;Kras^loxP-stop-loxP\ (LSL)-G12D^ mice,[@bib44] are born and reach adulthood with a normal pancreas, notwithstanding the expression of oncogenic Kras. Lesions occur spontaneously and stochastically, but can be accelerated and synchronized by the induction of acute pancreatitis.[@bib45], [@bib46], [@bib47] Thus, we induced acute pancreatitis in KF;Gli1^EGFP/+^ mice, and, as expected, we observed widespread PanIN development after 3 weeks. The 3-week time point was chosen because we and others have shown that this is when the pancreas parenchyma is almost completely replaced with low-grade PanIN lesions surrounded by an extensive fibroinflammatory reaction. Immunostaining for EGFP showed conspicuous positive staining limited to the stroma ([Figure 1](#fig1){ref-type="fig"}*E*). As in the healthy pancreas, staining was limited to the fibroblasts (αSMA^+^ and PDGFRβ^+^ cells) and not detected in epithelial cells.

Finally, to examine Gli1 in high-grade PanINs and pancreatic cancer, we generated KF;Trp53^FRT-stop-FRT/+^;Gli1^EGFP/+^ mice ([Figure 1](#fig1){ref-type="fig"}*F*). In these animals, FlpO recombinase activates the oncogenic Kras allele while also deleting 1 copy of the tumor-suppressor Trp53, thus essentially mimicking the commonly used KrasLSL-G12D; Trp53LSL-R172H/+; Pdx1-Cre model.[@bib48] These mice lived for approximately 20 weeks, until they reached humane end points. We observed that the expression of the EGFP reporter in this cohort resembled that of low-grade lesions, with prevalent stromal expression ([Figure 1](#fig1){ref-type="fig"}*G*). Gli1 has been found to be expressed in epithelial cells in a variable manner across tumor lines.[@bib28]^,^[@bib49] In this advanced disease progression model, we did not observe epithelial Gli1 expression. Thus, Gli1 expression is present in a small subset of fibroblasts in the normal pancreas and becomes more prevalent in the neoplastic pancreas, and in pancreatic cancer.

We used flow cytometry and PDGFRα as a cell surface marker for fibroblasts to obtain a quantitative measure of Gli1^+^ fibroblasts in the healthy and neoplastic pancreas. The expression of EGFP was limited to PDGFRα^+^ cells in healthy and neoplastic pancreata alike ([Figure 1](#fig1){ref-type="fig"}*H*), although we observed no or minimal expression of EGFP in CD45^+^ immune cells (data not shown). Among PDGFRα^+^ cells, the average EGFP expression was 21% in the healthy pancreas, 62% in low-grade lesions, and 39% in high-grade lesions/cancer ([Figure 1](#fig1){ref-type="fig"}*H*). Together, our data show that Gli1 expression is limited to a subset of fibroblasts in the healthy pancreas. In the neoplastic pancreas, Gli1 expression expands to a larger proportion of fibroblasts, a finding that might be explained by either de novo expression of Gli1 or expansion of Gli1^+^ cells.

Lineage Tracing Gli1^+^ Fibroblasts During Carcinogenesis {#sec1.2}
---------------------------------------------------------

We established a lineage tracing approach to follow the fate of Gli1^+^ fibroblasts from the healthy pancreas into the diseased organ. For this purpose, we bred mice with tamoxifen-inducible Cre recombinase (CreERT) in the Gli1 locus (Gli1^CreERT/+^) mice with mice conditionally expressing yellow fluorescent protein (YFP) or tandem dimer Tomato (tdTomato) tdTomato from the Rosa26 locus, Rosa26^LSL-YFP/LSL-YFP^, henceforth RYFP or Rosa26LSL-tdTomato (RTom) ([Figure 2](#fig2){ref-type="fig"}*A*). In the resulting dual-transgene progeny, administration of tamoxifen induced Cre recombination, permanently labeling those cells expressing Gli1 and their progeny. Importantly, labeling is transient, and thus any cell expressing Gli1 de novo, after the labeling period, would not be marked.Figure 2**CreERT model labels healthy adult Gli1-expressing fibroblasts.** (*A*) Genetic scheme for Gli1^CreERT/+^ crossed with either a Rosa26^YFP/+^ or a Rosa26^tdTomato/+^ reporter. (*B*) Experimental design for examining healthy adult mice expressing Gli1 in the pancreas. Adult mice ages 5--8 weeks were given tamoxifen gavages (4 mg/mouse/day) for 5 days. Tissue was examined 1 week after completing gavages. (*C*) IHC staining for YFP in healthy adult mice. *Scale bar*: 50 um. (*D*) IF staining of the following: Lyve-1 (green), Tomato (red), and DAPI (blue); NG2 (green), Tomato (red), and DAPI (blue); PDGFRβ (green), Tomato (red), and DAPI (blue); and αSMA (green), Tomato (red), and DAPI (blue) in Gli1^CreERT/+^;RTom samples. *Scale bar*: 50 um. (*E*) Genetic scheme for a Gli1^CreER/+^;Gli1^EGFP/+^,RTomato mouse model. (*F*) IF staining of GFP and Tomato in the Gli1^CreERT/+^;Gli1^EGFP/+^;RTom mouse. *Scale bar*: 50 um. (*G*) Representative YFP vs PDGFR⍺, flow cytometry plots of DAPI^-^ cells in a healthy Gli1^CreERT/+^;RYFP mouse and wild-type control and the quantification (n ≥ 10). (*H*) Representative YFP vs CD45 flow cytometry plot. (*I*) Quantification of the percentage of YFP^+^ cells that expressed CD45, PDGFR⍺, or CD105, as determined by flow cytometry gating. All data are expressed as means ± SEM. TAM, tamoxifen; TOM, Tomato; WT, wild-type.

To examine Gli1-expressing cells in the healthy pancreas, mice aged 5--8 weeks old were administered tamoxifen daily for 5 consecutive days by oral gavage, and then analyzed a week later ([Figure 2](#fig2){ref-type="fig"}*B*). As expected, immunostaining for YFP in Gli1^CreERT/+^;RYFP mice showed an expression pattern similar to the Gli1^EGFP^ mouse ([Figure 2](#fig2){ref-type="fig"}*C*). Labeled Gli1 cells often, but not exclusively, colocalized with fibroblast markers such as αSMA and PDGFRβ ([Figure 2](#fig2){ref-type="fig"}*D*). Gli1^+^ cells did not colocalize with Lyve-1^+^ lymphatic endothelial cells, although they were associated closely, but not overlapping, with NG2^+^ pericytes ([Figure 2](#fig2){ref-type="fig"}*D*).

We sought to evaluate the efficiency of lineage tracing in the healthy Gli1 population. We crossed Gli1^CreERT/+^;RTom mice into Gli1^EGFP/+^ mice to generate Gli1^CreERT/+^;Rtom;Gli1^EGFP/+^ transgenic animals, which allowed us to compare the real-time expression of Gli1 with short-term lineage tracing ([Figure 2](#fig2){ref-type="fig"}*E*). A week after tamoxifen administration, we harvested the healthy tissue and looked at the expression of the 2 fluorescent reporter genes. In this model, we found that the recombination-induced tdTomato expression was associated closely with EGFP expression ([Figure 2](#fig2){ref-type="fig"}*F*).

To obtain a quantitative measure of YFP in healthy Gli1^CreERT/+^;RYFP mice, we performed flow cytometry as previously described. On average, 3% of the PDGFRα-positive cells were labeled by YFP ([Figure 2](#fig2){ref-type="fig"}*G*). Consistent with our direct reporter, immune cells (CD45^+^) did not express YFP ([Figure 2](#fig2){ref-type="fig"}*H*). Of the YFP^+^ cells, the vast majority are PDGFRα-positive (82%), and approximately 30% of the YFP^+^ cells express CD105, a mesenchymal stromal marker ([Figure 2](#fig2){ref-type="fig"}*I*). Overall, our analysis showed that the Gli1CreERT allele recombined pancreatic fibroblasts, and approximately a sixth of the Gli1-expressing cells in the pancreas were labeled successfully. We estimated that this recombination efficiency was sufficient to track these cells during carcinogenesis.

Gli1^+^ Fibroblasts Expand During the Formation of Neoplastic Lesions in the Pancreas {#sec1.3}
-------------------------------------------------------------------------------------

Now with the inducible lineage-labeling model, we sought to determine the contribution of healthy Gli1^+^ fibroblasts to the fibrotic reaction of PanIN development. To that end, we crossed Gli1^CreERT/+^;RYFP mice with the KF model to generate KF;Gli1^CreERT/+^;R26YFP mice ([Figure 3](#fig3){ref-type="fig"}*A*). We administered tamoxifen to experimental and control mice when they reached 5--8 weeks of age, which is before the occurrence of spontaneous lesions. Then, we induced acute pancreatitis and harvested the tissue 3 weeks later ([Figure 3](#fig3){ref-type="fig"}*B*). We found YFP^+^ cells to be significantly more abundant in the neoplastic tissue than in the healthy tissue when visualized and analyzed by IHC ([Figure 3](#fig3){ref-type="fig"}*C* and *D*). As in the healthy pancreas, Gli1 expression was confined to the fibroblasts (PDGFRβ^+^) and excluded from ductal or acinar epithelial cells ([Figure 3](#fig3){ref-type="fig"}*E*). Gli1^CreERT/+^;RYFP mice without KF alleles exposed to the same treatment fully recovered from pancreatitis, and in these tissues YFP expression resembled that of untreated healthy mice ([Figure 3](#fig3){ref-type="fig"}*F*).Figure 3**Gli1**^**+**^**fibroblasts lineage-traced before pancreatitis-induced PanIN lesion formation contribute to the stroma.** (*A*) Genetic scheme for a KF;Gli1^CreERT/+^;RYFP mouse. (*B*) Experimental design for labeling healthy Gli1^+^ cells before PanIN generation. Adult mice 5--8 weeks old were given 5 tamoxifen gavages and rested for a week before 2 days of cerulein injections to induce pancreatitis. After 3 weeks, samples were collected. (*C*) IHC staining for YFP in KF;Gli1^CreERT/+^;RYFP and KF control tissue (*inset*) labeled before PanIN generation. *Scale bar*: 100 um. (*D*) Quantification of YFP^+^ staining area from IHC (n ≥ 8) (*E*) IF staining on KF;Gli1^CreERT/+^;RYFP and KF control (*inset*) samples of YFP (green), PDGFRβ (red), cytokeratin 19 (CK19) (white), and 4′,6-diamidino-2-phenylindole (DAPI) (blue); YFP (green), αSMA (red), amylase (pink), and DAPI (blue); YFP (green), podoplanin (red), E-cadherin (white), and DAPI (blue); and YFP (green), CD105 (red), and DAPI (blue). *Scale bar*: 50 um. (*F*) A representative YFP IHC image of a Gli1^CreERT/+^;RYFP mouse that followed the same labeling scheme. *Scale bar*: 100 um. AMY, amylase; ECAD, E-cadherin; TAM, tamoxifen; WT, wild-type.

To determine whether Gli1^+^ progeny persisted through cancer progression and in the context of spontaneous carcinogenesis, we generated Ptf1a^FlpO/+^;Kras^FRT-stop-FRT-G12D/+^ (KPF);Gli1^CreERT/+^;RYFP mice ([Figure 4](#fig4){ref-type="fig"}*A*). We administered tamoxifen as these animals reached early adulthood (age, 5--8 wk), and then let them develop lesions with time ([Figure 4](#fig4){ref-type="fig"}*B*). We harvested the pancreata when the mice were expected to harbor both high-grade PanIN lesions and malignant disease, approximately 18 weeks after labeling, and found abundant YFP^+^ cells derived from Gli1^+^ progenitors ([Figure 4](#fig4){ref-type="fig"}*C* and *D*).Figure 4**Gli1**^**+**^**fibroblasts contribute to the stroma when lineage-traced in a spontaneous pancreatic carcinogenesis model.** (*A*) Genetic scheme for a KPF;Gli1^CreERT/+^;RYFP mouse. (*B*) Experimental design for labeling healthy Gli1^+^ cells before spontaneous carcinogenesis. Adult mice 5--8 weeks old were given 5 tamoxifen gavages, aged, and then harvested on evidence of disease burden. (*C*) IHC staining for YFP in KPF;Gli1^CreERT/+^;RYFP and KPF control (*inset*) mice. *Scale bar*: 100 um. (*D*) IF staining for YFP (green), αSMA (red), amylase (gray), and DAPI (blue); and YFP (green), podoplanin (red), E-cadherin (white), and DAPI (blue) in KPF;Gli1^CreERT/+^;RYFP and KPF control (*inset*) samples. *Scale bar*: 50 um. (*E*) Merged and single-channel IF images for YFP (green), αSMA (red), and DAPI (blue) in KF and KPF Gli1^CreER^;RYFP samples. *Scale bar*: 50 um. (*F*) IF quantification of the percentage of αSMA^+^ cells that co-expressed YFP in lineage-traced KF and KPF samples (n ≥ 5). (*F*) IF quantification of the percentage of YFP^+^ cells that co-expressed αSMA in lineage-traced KF and KPF samples (n ≥ 8). All data are expressed as means ± SEM. AMY, amylase; TAM, tamoxifen.

Unlike the normal pancreas, the neoplastic tissue contains a myofibroblast-like population characterized by the expression of αSMA.[@bib14] We observed partial co-localization of YFP and αSMA in both KF and KPF lineage models ([Figure 4](#fig4){ref-type="fig"}*E*). By quantifying the dual IF stain, we observed lineage-traced Gli1^+^ cells on average contributed to a little less than half of the total myofibroblast population ([Figure 4](#fig4){ref-type="fig"}*F*). Conversely, the majority of our lineage-traced Gli1^+^ cells are myofibroblastic: an average of 70% of the YFP^+^ cells in both models co-expressed αSMA ([Figure 4](#fig4){ref-type="fig"}*F*, lower panel). Thus, we showed that healthy resident Gli1^+^ fibroblasts expand and contribute to the αSMA^+^ myofibroblast population during carcinogenesis.

The Pancreas Is Home to Heterogeneous Fibroblast Populations That Differentially Contribute to the Neoplastic Stroma {#sec1.4}
--------------------------------------------------------------------------------------------------------------------

We then sought to determine whether all pancreatic fibroblast populations expand during carcinogenesis. For this purpose, we sought to track a different population of fibroblasts, namely Hoxb6^+^ cells. The homeobox factor Hoxb6 is widely expressed in the mesenchyme of the developing pancreas, and regulates the embryonic development of the organ.[@bib36] To assess the expression of Hoxb6 in the adult pancreas, we followed a similar strategy to that described before for Gli1. We generated Hoxb6^CreERT/+^;RYFP or Hoxb6^CreERT/+^;RTom mice, administered tamoxifen once they reached adulthood, and harvested the tissues 1 week later ([Figure 5](#fig5){ref-type="fig"}*A* and *B*). Interestingly, the distribution of Hoxb6^+^ fibroblasts appeared different than that of Gli1^+^ fibroblasts, with the former being interspersed in the pancreas parenchyma, rather than concentrated around blood vessels and ducts ([Figure 5](#fig5){ref-type="fig"}*C*). Similar to Gli1, Hoxb6 labels a small subset of cells in the adult pancreas and is limited to fibroblasts, with no expression in other cell compartments, including endothelial cells ([Figure 5](#fig5){ref-type="fig"}*D--G*).Figure 5**Hoxb6 labels a subset of mesenchymal cells in the healthy pancreas.** (*A*) Genetic scheme for Hoxb6^CreERT/+^ crossed with either a RYFP reporter or RTomato reporter. (*B*) Experimental protocol for examining healthy adult mice expressing Hoxb6 in the pancreas. Adult mice aged 5--8 weeks were given tamoxifen gavages (4 mg/mouse/day) for 5 days. Tissue was examined 1 week after completing gavages. (*C*) IHC staining for YFP in healthy adult mice. *Scale bar*: 50 um. (*D*) IF staining of αSMA (green), Tomato (red), and 4′,6-diamidino-2-phenylindole (DAPI) (blue); CD31 (green), Tomato (red), and DAPI (blue); vimentin (green), Tomato (red), and DAPI (blue); and PDGFRβ (green), Tomato (red), and DAPI (blue) in healthy Hoxb6^CreERT/+^;RTom tissue. *Scale bar*: 50 um. (*E*) Representative YFP vs PDGFR⍺^+^ flow cytometry plots of DAPI^-^ cells in a Hoxb6^CreERT/+^;RYFP mouse and wild-type control and the quantification (n ≥ 5). (*F*) Representative YFP vs CD45 flow cytometry plot. (*G*) Quantification of the percentage of YFP^+^ cells that expressed CD45, PDGFR⍺, or CD105 as determined by flow cytometry gating. All data are expressed as means ± SEM. TAM, tamoxifen; VIM, vimentin; WT, wild-type.

To determine whether Gli1^+^ and Hoxb6^+^ fibroblasts indeed represent different cell populations, we generated Hoxb6^CreERT/+^;RTom;Gli1^EGFP/+^ mice to dual label the populations ([Figure 6](#fig6){ref-type="fig"}*A*). To maximize labeling of Hoxb6^+^ cells, we first administered tamoxifen by oral gavage, as previously described, and then placed the mice on tamoxifen chow for 3 weeks before harvesting the tissue ([Figure 6](#fig6){ref-type="fig"}*B*). Although the low frequency of each cell population complicated the analysis, we detected single-labeled tdTomato^+^ or EGFP^+^ cells, and, less frequently, cells expressing both reporters ([Figure 6](#fig6){ref-type="fig"}*C*). To obtain a quantitative measure, we performed flow cytometry on the pancreata from mice expressing 1 or both reporters. In Hoxb6^CreERT/+^;RYFP mice, an average of 6% of the PDGFRα^+^ fibroblasts were labeled with the reporter ([Figure 5](#fig5){ref-type="fig"}*E*). In the dual-labeled Hoxb6^CreERT/+^;RTom;Gli1^EGFP/+^ mice, we observed closer to 20% PDGFRα^+^ cells that only expressed tdTomato, the Hoxb6 marker ([Figure 6](#fig6){ref-type="fig"}*D*). The higher incidence of Hoxb6 in the later experiment can be attributed to the additional 3 weeks of tamoxifen chow, allowing a more complete recombination, and a stronger fluorophore to detect in flow cytometry. In the Hoxb6^CreERT/+^;RTom;Gli1^EGFP/+^ mice, approximately 10% of PDGFRα^+^ cells express both Hoxb6 and Gli1, although of course this number is dependent on the recombination efficacy of the inducible Cre ([Figure 6](#fig6){ref-type="fig"}*D*). Overall, we concluded that Hoxb6 expression sufficiently captures a healthy mesenchymal cell population within the healthy pancreas, largely distinct from fibroblasts that express Gli1.Figure 6**Hoxb6 and Gli1 are expressed in different populations.** (*A*) Genetic scheme for a Hoxb6^CreERT/+^;RTom;Gli1^EGFP/+^ mouse model. (*B*) Experimental design for examining healthy Hoxb6^CreERT/+^;RTom;Gli1^EGFP/+^ mice. Adult mice aged 5--8 weeks were given tamoxifen gavages (4 mg/mouse/day) for 5 days. Mice then were placed on tamoxifen chow for 3 weeks. Tissue was examined 1 week after completing chow regimen. (*C*) IF staining of GFP and Tomato in the Hoxb6^CreERT/+^;RTom;Gli1^EGFP/+^ mouse. *Scale bar*: 50 um. (*D*) Flow cytometry quantification of the percentage of healthy CD45^-^ PDGFR⍺^+^ cells that expressed Tomato, GFP, or both (n ≥ 6). All data are expressed as means ± SEM. RTOM, Rosa26LSL-tdTomato; TAM, tamoxifen.

Taking advantage of these separate fibroblast markers, we addressed whether healthy resident fibroblasts expand equally during carcinogenesis. For this purpose, we generated KF;Hoxb6^CreERT/+^;RYFP mice ([Figure 7](#fig7){ref-type="fig"}*A*). We labeled Hoxb6^+^-expressing cells before lesion formation, and harvested the tissue 3 weeks after inducing pancreatitis, as described earlier for Gli1^+^-traced animals ([Figure 7](#fig7){ref-type="fig"}*B*). As expected, the pancreas parenchyma in these animals was replaced by widespread PanIN lesions and surrounding stroma, and mice without KF alleles fully recovered from pancreatitis ([Figure 7](#fig7){ref-type="fig"}*C*). Within the stroma, labeled fibroblasts were rare ([Figure 7](#fig7){ref-type="fig"}*D* and *E*). Flow cytometry analysis confirmed these observations: although Gli1^+^ cells give rise to an average of 14% of the fibroblasts within the stroma, Hoxb6^+^ cells give rise to only 2% ([Figure 7](#fig7){ref-type="fig"}*F*).Figure 7**Hoxb6**^**+**^**fibroblasts do not contribute to the pancreatic stroma.** (*A*) Genetic scheme for the KF;Hoxb6^CreERT/+^;RYFP model. (*B*) Experimental design for labeling healthy Hoxb6^+^ cells before PanIN generation. Adult mice 5--8 weeks old were given 5 tamoxifen gavages and rested a week before 2 days of cerulein injections to induce pancreatitis. After 3 weeks, mice were harvested. (*C*) A representative YFP IHC image of a Hoxb6^CreERT/+^;RYFP mouse following the protocol. *Scale bar*: 100 um. (*D*) IHC staining for YFP in KF;Hoxb6^CreERT/+^;RYFP and KF control (*inset*) mice labeled before PanIN generation. *Scale bar*: 100 um. (*E*) IF staining panels of YFP (green), PDGFRβ (red), cytokeratin 19 (CK19) (white), DAPI (blue); and YFP (green), αSMA (red), amylase (pink), and DAPI (blue) in KF;Hoxb6^CreERT/+^;RYFP mice labeled before PanIN generation. *Scale bar*: 50 um. (*F*) Flow cytometry quantification of the percentage of CD45^-^ PDGFR^+^ cells that expressed YFP in lineage-traced Gli1 and Hoxb6 mice and their controls (n ≥ 5). (*G*) Experimental design for labeling after PanIN generation. Adult mice 5--8 weeks old were given cerulein injections, rested for 2 weeks, and then given 5 gavages of tamoxifen before tissue collection. (*H*) IHC staining for YFP in KF;Gli1^CreERT/+^;RYFP and KF;Hoxb6^CreERT/+^;RYFP mice labeled after PanIN generation. *Inset* shows KF control. *Scale bar*: 100 um. (*C*) Flow cytometry quantification of the percentage of CD45^-^PDGFR^+^ cells that express YFP in KF;Gli1^CreERT/+^;RYFP and KF;Hoxb6^CreERT/+^;RYFP mice labeled after PanIN generation (n ≥ 3). All data are expressed as means ± SEM. AMY, amylase.

We then altered our experimental design, inducing pancreatitis in adult mice, and then inducing Cre recombination 2 weeks later to examine the overall expression of Gli1 and Hoxb6 in PanINs, and to determine the extent of de novo expression of either marker. The pancreata were harvested 3 weeks after the induction of pancreatitis in this experiment ([Figure 7](#fig7){ref-type="fig"}*G*). IHC and flow cytometry analysis showed a slightly higher prevalence of Gli1^+^ fibroblasts (an average of 20% of PDGFRα^+^ cells) than in the samples labeled before PanIN formation, suggesting that Gli1 may be activated de novo in cells that were not expressing it previously ([Figure 7](#fig7){ref-type="fig"}*H* and *I*). In contrast, the expression of Hoxb6 still was minimal and observed in only approximately 2% of the PDGFRα^+^ fibroblasts.

To expand on an observation that Gli1^+^-traced cells often remained near neoplastic epithelial cells, we revisited the KF;Gli1^CreERT/+^;RYFP samples and examined areas of lesser lesion burden. In those areas, we noticed that the lineage-traced Gli1^+^ cells often surrounded the nascent areas of acinar to ductal metaplasia and PanINs ([Figure 8](#fig8){ref-type="fig"}*A*). Because a subset of pancreatic fibroblasts in PDAC are described as αSMA^+^ myofibroblast-CAFs (myCAFs) and are positioned adjacent to the epithelial neoplastic cells,[@bib14] we co-stained our lineage-traced Gli1^+^ cells with αSMA again. The resulting staining around these early lesions suggested occasional colocalization, but not all YFP^+^ cells were αSMA^+^, and not all αSMA^+^ cells were YFP^+^ ([Figure 8](#fig8){ref-type="fig"}*B*). Thus, Gli1^+^ progeny may be early contributors to the myCAF population, but even at this earliest stage, CAF heterogeneity is present.Figure 8**Lineage-traced Gli1 fibroblasts are present around the earliest lesion development.** (*A*) IHC staining for YFP in KF;Gli1^CreERT/+^;RYFP mice labeled before PanIN generation. *Scale bar*: 100 um. (*B*) IF merged and single-channel images for YFP (green), αSMA (red), and amylase (pink) in KF;Gli1^CreERT/+^;RYFP mice. *Scale bar*: 50 um. AMY, amylase.

In summary, our data show that the healthy pancreas is home to heterogenous fibroblast populations, which have a differential potential to expand during the process of carcinogenesis. Although we were able to lineage trace 2 of these populations, our data also indicate that other progenitors for the fibrotic stroma must exist to contribute to the remaining fibroblast populations.

Discussion {#sec2}
==========

In the pancreas, the mesenchyme surrounds and supports epithelium development[@bib50] and differentiates to form cell types such as fibroblasts, pancreatic stellate cells, and pericytes.[@bib51]^,^[@bib52] Activated fibroblasts, also known as myofibroblasts, help regulate wound repair and recovery,[@bib53]^,^[@bib54] but in the context of certain pancreatic diseases, such as chronic pancreatitis and pancreatic cancer, the fibrosis is not resolved. Fibroblasts thus are an abundant, active, and heterogeneous player within the tumor microenvironment of pancreatic adenocarcinoma. Currently, functionally distinct subclasses of CAFs have been defined in other cancers such as breast carcinoma,[@bib55]^,^[@bib56] colorectal carcinoma,[@bib57] and lung adenocarcinoma.[@bib58] In pancreatic cancer, a putative mesenchymal stem cell population has been identified in mouse and human samples,[@bib16]^,^[@bib17] and CAFs have been classified into myCAF, inflammatory-CAF, and antigen-presenting-CAF (apCAF) populations with potentially distinct functions and activation pathways.[@bib14]^,^[@bib15]^,^[@bib20]

Here, we sought to determine which fibroblasts in the healthy pancreas give rise to CAFs during the progression of carcinogenesis. A population of pancreatic stellate cells, containing lipid droplets with vitamin A deposits, similar to liver hepatic stellate cells, has been described,[@bib37]^,^[@bib59]^,^[@bib60] and traditionally is considered the source of the fibrotic reaction in pancreatic cancer. However, no experimental validation supports the notion that stellate cells lead to CAFs. Recent single-cell transcriptomic profiles of healthy or low-grade lesion fibroblast populations have been mapped in silico to CAFs, which suggests that resident pancreatic fibroblasts do contribute to CAFs.[@bib23]^,^[@bib25] To directly trace resident fibroblast populations, however, we first needed to define markers of distinct populations of fibroblasts.

We characterized 2 different populations of pancreatic fibroblasts present in the healthy organ by the expression of the transcription factors Gli1 and Hoxb6. Gli1 is a target gene and transcriptional effector of the Hedgehog signaling pathway (see Lau et al[@bib29] and Hui et al[@bib61]). Hedgehog signaling is active throughout embryonic development of the gastrointestinal tract, but needs to be suppressed to allow for the formation of the pancreas anlage.[@bib61], [@bib62], [@bib63] However, some low level of Hedgehog signaling persists[@bib64] to maintain homeostasis and assist in injury recovery.[@bib32]^,^[@bib65]^,^[@bib66] Thus, we found that a subset of fibroblasts in the healthy pancreas consistently express Gli1 and do not have characteristics of stellate cells. Meanwhile, Hoxb6 is expressed throughout the mesenchyme of the developing pancreas,[@bib36] and in a portion of fibroblasts in the adult organ. Although there is partial overlap in Gli1- and Hoxb6-expressing cells, largely they consist of separate populations. We thus set out to lineage trace these populations with the goal to answer the following questions: (1) whether either fibroblast population gives rise to CAFs; (2) whether all fibroblast populations expand during carcinogenesis; and (3) whether different functional CAF subpopulations derive from different progenitors in the healthy pancreas.

Gli1^+^ fibroblasts have been lineage-traced in several organ fibrosis models. After injury, the majority of Gli1^+^ cells acquire αSMA expression and contribute to fibrosis. Approximately 40% of myofibroblasts in the kidney, liver, and lung, and 60% of myofibroblasts in the heart originated from tissue-resident Gli1^+^ progenitors after a fibrosis-inducing injury.[@bib32]^,^[@bib33] In addition, Gli1 progenitors contribute approximately half of the myofibroblasts in instances of endochondral heterotopic ossification and bone marrow fibrosis.[@bib31]^,^[@bib35] Gli1^+^ fibroblasts have not been characterized in the pancreas, and their contribution to tumor-associated fibroblasts has not yet been studied. We found Gli1 to be expressed in a minority of healthy PDGFRα^+^ fibroblasts and localized in a perivascular position adjacent to pericytes. When we lineage-traced the progeny of healthy Gli1^+^ fibroblasts, we found they expanded in quantity and contributed to CAFs.

Hoxb6 is a developmental transcription factor expressed prominently in the pancreas mesoderm until embryonic day 16.5.[@bib36] We showed that Hoxb6 expression is present in the healthy mouse pancreas in a portion of PDGFRα^+^ fibroblasts, but not in immune cells. We had hypothesized that this fibroblast subpopulation would expand and contribute to the fibrotic stroma in a similar manner as the Gli1^+^ population owing to the relative prevalence of the cells and the occasional overlap between Hoxb6 and Gli1 expression. Interestingly, as we lineage-traced Gli1 and Hoxb6 cells from the healthy pancreas into carcinogenesis, we found that they contributed in a very different manner to the stroma. Although Gli1^+^ fibroblasts expanded during carcinogenesis, Hoxb6^+^ cells failed to do so. Furthermore, the expression of Gli1 was extensive in lesions and advanced disease, while Hoxb6 expression did not increase.

Our findings suggest that not all resident fibroblast populations expand and transition into cancer-associated fibroblasts within the pancreas, and that fibroblasts are heterogenous with separate functional roles even at the healthy stage. Gli1^+^ cells likely are contributing to a portion of the tumor-associated myCAF population, although it is worth noting that even within the Gli1^+^ cells of the healthy pancreas, there is heterogeneity. For instance, a subset of Gli1 and Hoxb6 cells express CD105, a mesenchymal stromal marker. This could indicate heterogeneity or perhaps a distinct activation state within the population. In addition, a subset of Gli1^+^ cells express Hoxb6. This dual-positive population does not appear to proliferate because we observed minimal Hoxb6^+^ fibroblasts among the PanIN stroma when we lineage-traced Hoxb6^+^ cells. However, Hoxb6^+^ fibroblasts conceivably could be proliferating and dying before our analysis time points. Unfortunately, because Hoxb6 has close homology with other homeobox genes, further antibody or RNA-based investigation is hindered. Instead, further investigation into the fate, function, and drivers of other fibroblast populations is needed to best comprehend the complexity of the fibrotic reaction. Different CAF subpopulations may derive from different progenitors, as suggested in an experiment in which the single-cell transcriptional profiles of 2 healthy fibroblast populations mapped closer to the tumor-associated myCAF or inflammatory-CAF populations than to themselves.[@bib23]

Understanding the complexity of fibroblasts in healthy organs and disease has been hampered by the limited availability of specific markers. Pancreatic cancer fibroblasts have long been assumed to derive from resident stellate cells,[@bib37] with no in vivo experimental support. Here, we show that nonstellate cell fibroblast populations exist in the pancreas and they have the ability to expand during carcinogenesis. In addition, we determined that the ability to contribute to the cancer-associated stroma during carcinogenesis is unique to only some fibroblast subsets in the pancreas. We found Gli1^+^ fibroblasts gave rise to less than half of the total fibroblast population during carcinogenesis. This is likely a conservative figure based on imperfect recombination efficiency, but it nonetheless indicates that other subsets must exist in the healthy organ with the ability to expand. Alternative sources of the CAFs may arise from other resident fibroblast populations, circulating progenitor cells from the bone marrow, or pericytes (reviewed by LeBleu[@bib6] and El Agha[@bib67]). Overall, these findings are consistent with fate-mapping experiments performed in the liver,[@bib32]^,^[@bib68] kidney,[@bib32]^,^[@bib69] heart,[@bib32]^,^[@bib70] lung,[@bib32]^,^[@bib71]^,^[@bib72] spinal cord,[@bib73] bone,[@bib31] and skin,[@bib74] in which resident fibroblasts proliferate in response to injury to contribute, at least partially, to organ fibrosis. Our findings advance our understanding of how the pancreatic fibroinflammatory environment is established during carcinogenesis and offer new directions with which to examine the main stromal regulators of carcinogenesis, and, eventually, improve patient outcome.

Materials and Methods {#sec3}
=====================

Mouse Strains {#sec3.1}
-------------

All mouse protocols were conducted with approval from the University Committee on Use and Care of Animals. Gli1^EGFP/+^ mice[@bib75] were crossed with KF or KPF mouse models donated by Dr Crawford[@bib43] to generate KF;Gli1^EGFP/+^ and KPF;Gli1^EGFP/+^ crosses. Gli1^CreERT/+^ (The Jackson Laboratory, Bar Harbor, ME, \#007913) or Hoxb6^CreERT/+^ (contributed by Dr Wellik[@bib76]) mice were crossed into Rosa26^YFP/+^ (The Jackson Laboratory, \#006148) or Rosa26^Tom/+^ (The Jackson Laboratory, \#007909) reporter mice. These mice then were crossed further with the KF and KPF mice. Experimental and control animals were treated in parallel. Mice were housed in specific pathogen-free facilities at the University of Michigan Rogel Cancer Center.

In Vivo Experiments {#sec3.2}
-------------------

All experiments were initiated in adult mice between 5 and 8 weeks of age. Acute pancreatitis was induced over 2 days. For 8 hours each day, mice received hourly intraperitoneal injections of cerulein (Sigma-Aldrich, St. Louis, MO) as previously described.[@bib47]^,^[@bib77] To activate the CreERT transgene, mice received 4 mg tamoxifen in corn oil/3% ethanol (Sigma-Aldrich) per day via oral gavage for 5 days. Where mentioned, mice received an additional 3 weeks of tamoxifen chow (400 tamoxifen citrate mg/kg diet; Envigo, Indianapolis, IN).

Immunohistochemistry and Immunofluorescence {#sec3.3}
-------------------------------------------

All immunohistochemical and immunofluorescent stains were performed as previously described.[@bib78] Primary antibodies used were as follows: YFP (1:200; Abcam, Cambridge, MA), PDGFRβ (1:100; Abcam), cytokeratin 19 (1:50; Iowa Developmental Hybridoma Bank, Iowa City, IA), αSMA (1:1000; Sigma-Aldrich), amylase (1:100; Sigma), epithelial cell adhesion molecule (1:300; Cell Signaling, Danvers, MA), podoplanin (1:300; BioLegend, San Diego, CA), CD31 (1:50; Cell Signaling), vimentin (1:100; Cell Signaling), neuron-glial antigen (1:100; Abcam), and lymphatic vessel endothelial receptor 1 (1:100; Abcam). Images were taken with an Olympus BX-51 microscope, and CellSens (Olympus, Center Valley, PA) standard software. For IF, Alexa Fluor--conjugated (Invitrogen, Carlsbad, CA) secondary antibodies were used. Prolong Gold--4′,6-diamidino-2-phenylindole (Invitrogen) was used to counterstain the cell nuclei. The images were acquired using a Nikon A1 inverted confocal microscope and NIS-Elements software (Nikon, Melville, NY). At least 5 separate 60× fields (\>180 cells) for IF or 20× fields for IHC from more than 1 experimental sample were quantified using HALO software (Perkin Elmer, Waltham, MA).

TEM {#sec3.4}
---

Tissues for transmission electron microscope analysis were prepared by the University of Michigan Microscopy Core and images were acquired using a Philips CM-100 transmission electron microscope (FEI, Hillsboro, Oregon).

Flow Cytometry {#sec3.5}
--------------

Pancreatic single-cell suspensions were prepared as described[@bib79] by mincing the tissue and then digesting in 1 mg/mL collagenase V (Sigma-Aldrich) at 37°C for 15--20 minutes. Digested samples were filtered through a 40-μm strainer and subjected to a red blood cell lysis step. Samples were submitted for flow analysis in Hank's balanced salt solution with 2% fetal bovine serum. Antibodies were used in combinations of the following: CD45-Pacific Orange (1:50; BD Pharmingen, Franklin Lakes, NJ), PDGFR⍺-Phycoerythrin (1:50; BD Pharmingen), and PDGFR⍺-Phycoerythrin-Cy7 (1:50; BD Pharmingen). Fluorescence-activated cell sorting was performed on a MoFlo Astrios (Beckman Coulter) and data were analyzed using Summit 6.1 Software (Beckman Coulter, Brea, CA) and FlowJo 10.6 (FlowJo, Ashland, OR). The gating strategy was as follows: cells were first selected on forward (FSC-Area) and side (SSC-Area) scatters to exclude debris. Then single cells were gated based on SSC-Height vs SSC-Width and FSC-Height vs FSC-Width parameters. Alive cells were selected from an SSC-Height vs 4′,6-diamidino-2-phenylindole plot. Nonimmune cells were selected from an SSC-Height vs CD45-Pacific Orange plot. At least 1 × 10^5^ events that pass these selection parameters were recorded for each sample. Further gating based on PDGFR, YFP, and Tomato parameters was used to analyze and sort the cells.

Statistical Analysis {#sec3.6}
--------------------

The Student *t* test with Welch correction or nonparametric Brown--Forsythe and Welch analysis of variance using the Dunnett T3 multiple comparisons tests were performed using Prism 8 (GraphPad, San Diego, CA) software to analyze the statistical differences between experimental cohorts. Significance was established for *P* values less than .05. All data are presented as means ± standard error of the mean (SEM).
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